View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Ahold Delhaize: 2Q25 pre-close call feedback. Azelis: Attractive acquisition in personal care Italy. Econocom: Two UK/Ireland AV acquisitions disclosed. Staffing: Better French volumes in May even with easier comps, June outlook sluggish. Staffing: Dutch figs Period 6 volume and revenues weaker on tougher comps. UCB: Trump threatens a 200% tariff on pharmaceutical products

H & M Hennes & Mauritz AB: 1 director

A director at H & M Hennes & Mauritz AB bought 3,200,000 shares at 136.649SEK and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...

Carole Braudeau
  • Carole Braudeau

Credit Morning 07/02/2025

Afflelou: the Afflelou family grows its stake but the company announced a double dividend recap|Sabadell sells TSB to Santander for £2.9 bn|

Carole Braudeau
  • Carole Braudeau

Morning Crédit 02/07/2025

Afflelou : la famille se renforce au capital mais le groupe réalise un double dividend recap|Sabadell cède TSB à Santander pour 2.9 mds GBP|

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

ASR: Buyout deal, second in as many months, similar size (€660m). Flow Traders: Sticky digits. IMCD: Small but solid acquisition in India. Randstad: Preliminary preview of 2Q25F results due 23 July. UCB: Fintepla meets primary endpoint in CDKL5 Deficiency Disorder

Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Thibault Leneeuw
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
Thomas Vranken
  • Thomas Vranken

UCB FIRST LOOK: Fintepla scores Phase 3 win in third epileptic indicat...

UCB announced positive Phase 3 results for Fintepla in treating CDKL5 deficiency disorder (CDD), a rare and severe early-onset epileptic condition with limited treatment options. The randomized, placebo-controlled study in patients aged 1–35 met its primary and secondary endpoints, showing a significant reduction in countable motor seizures and a favourable safety profile. UCB plans to announce the full dataset at an upcoming conference and seek regulatory approval promptly. This marks Fintepla'...

ABGSC Retail Research ... (+3)
  • ABGSC Retail Research
  • Benjamin Wahlstedt
  • Fredrik Ivarsson
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch